A comparison of remifentanil and alfentanil for use with propofol in patients undergoing minimally invasive coronary artery bypass surgery

被引:17
作者
Ahonen, J
Olkkola, KT
Verkkala, K
Heikkinen, L
Järvinen, A
Salmenperä, M
机构
[1] Univ Helsinki, Cent Hosp, Dept Anesthesia, FIN-00029 HYKS, Finland
[2] Univ Helsinki, Cent Hosp, Dept Thorac & Cardiovasc Surg, FIN-00029 HYKS, Finland
[3] Univ Helsinki, Helsinki, Finland
关键词
D O I
10.1097/00000539-200006000-00003
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Most patients undergoing minimally invasive direct coronary artery bypass surgery can be awakened and tracheally extubated in the operating room. We have compared two techniques of total IV anesthesia in this patient population: 30 patients (aged 44 to 74 yr; 24 male) premedicated with temazepam were randomly assigned to receive either remifentanil-propofol or alfentanil-propofol. Anesthesia was induced with remifentanil 2 mu g/kg or with alfentanil 40 mu g/kg, with propofol, and maintained with remifentanil at 0.25 or 0.5 mu g.kg(-1).min(-1) or alfentanil at 0.5 or 1 mu g.kg(-1).min(-1). The stable maintenance infusion rate of propofol was adjusted for age. Times to awakening and tracheal extubation were recorded. Postoperatively, IV morphine provided by patient-controlled analgesia was used for 48 h. Times to awakening and tracheal extubation (mean +/- SD) were shorter (P < 0.01) in patients receiving remifentanil, and interpatient variations in times to awakening and tracheal extubation smaller (awakening 25 +/- 7 vs 74 +/- 32 min, and extubation 27 +/- 7 vs 77 +/- 32 min). Analysis of variance revealed that postoperative consumption of morphine was dependent on both the intraoperative opioid and the time elapsed after surgery (P < 0.05): patient-controlled analgesia morphine use during the first 3 h after awakening was more in patients receiving remifentanil (P < 0.01).
引用
收藏
页码:1269 / 1274
页数:6
相关论文
共 26 条
[1]   Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting [J].
Ahonen, J ;
Olkkola, KT ;
Salmenpera, M ;
Hynynen, M ;
Neuvonen, PJ .
ANESTHESIOLOGY, 1996, 85 (06) :1246-1252
[2]   Lack of effect of antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam [J].
Ahonen, J ;
Olkkola, KT ;
Neuvonen, PJ .
THERAPEUTIC DRUG MONITORING, 1996, 18 (02) :124-127
[3]   Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions [J].
Bertz, RJ ;
Granneman, GR .
CLINICAL PHARMACOKINETICS, 1997, 32 (03) :210-258
[4]  
COE V, 1995, J CARDIOTHOR VASC AN, V9, P37
[5]   Remifentanil pharmacokinetics in obese versus lean patients [J].
Egan, TD ;
Huizinga, B ;
Gupta, SK ;
Jaarsma, RL ;
Sperry, RJ ;
Yee, JB ;
Muir, KT .
ANESTHESIOLOGY, 1998, 89 (03) :562-573
[6]   Remifentanil versus alfentanil - Comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers [J].
Egan, TD ;
Minto, CF ;
Hermann, DJ ;
Barr, J ;
Muir, KT ;
Shafer, SL .
ANESTHESIOLOGY, 1996, 84 (04) :821-833
[7]   Determination of the potency of remifentanil compared with alfentanil using ventilatory depression as the measure of opioid effect [J].
Glass, PSA ;
Iselin-Chaves, IA ;
Goodman, D ;
Delong, E ;
Hermann, DJ .
ANESTHESIOLOGY, 1999, 90 (06) :1556-1563
[8]  
GLASS PSA, 1993, ANESTH ANALG, V77, P1031
[9]  
GLASS PSA, 1995, J CARDIOTHOR VASC AN, V9, P16
[10]   CONTEXT-SENSITIVE HALF-TIME IN MULTICOMPARTMENT PHARMACOKINETIC MODELS FOR INTRAVENOUS ANESTHETIC DRUGS [J].
HUGHES, MA ;
GLASS, PSA ;
JACOBS, JR .
ANESTHESIOLOGY, 1992, 76 (03) :334-341